Honda CB125 Hornet launched: Prices, key details about Hero Xtreme 125R rival
has officially launched the CB125 Hornet, pricing it at Rs 1.12 lakh, ex-showroom. Unveiled just recently, this new offering now becomes the most premium bike in Honda's 125cc lineup. Positioned above the Shine and SP125, the CB125 Hornet is set to challenge segment leaders like the
TVS Raider
and
Hero Xtreme 125R
. Here's what makes this new contender has to offer.
Honda CB125 Hornet launched: Key details
The CB125 Hornet gets a sharp and aggressive design. The bike features a pair of twin-LED headlamps and a muscular fuel tank with bold shrouds on the sides. A two-piece seat setup and upswept exhaust complete its sporty look.
At the heart of the CB125 Hornet is a 123.94cc single-cylinder engine that makes 11 hp and 11.2 Nm of torque. The engine is mated to a 5-speed gearbox. Honda says that the bike accelerates from 0 to 60 kmph in just 5.4 seconds, making it one of the quickest in the 125cc class.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
You will never turn off your computer again.
planetcapture.io
Undo
Honda Shine 100 Review: Real-world fuel efficiency tested! | TOI Auto
In terms of tech, the CB125 Hornet gets a 4.2-inch TFT display with Bluetooth connectivity via the Honda RoadSync app. Riders can use it for turn-by-turn navigation, call and SMS alerts, and even music playback through a connected headset.
Suspension duties are handled by gold-finished USD front forks — a first in this segment — and a rear mono-shock with adjustable preload. The braking setup includes a 240 mm disc at the front and a drum brake at the rear, paired with single-channel ABS for added safety. The CB125 Hornet is available in four colour options, including dual-tone options such as Pearl Siren Blue with Lemon Ice Yellow and Pearl Siren Blue with Sports Red.
Discover everything about the
automotive
world at
Times of India
.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Relief for India as China agrees to lift curbs on rare earth, fertiliser exports
Wang Yi, S Jaishankar NEW DELHI: External affairs minister S Jaishankar's meeting with counterpart Wang Yi saw efforts by both sides to address each other's concerns and interests, with Beijing agreeing to remove curbs on export of fertilisers, rare earth minerals and tunnel boring machines to cater to India's needs. Indian authorities said these were three key concerns raised in the meeting. Both sides also agreed to re-opening border trade through designated trading points, namely Lipulekh, Shipki La and Nathu La. Wang brought up Taiwan and Jaishankar stressed there had been no change in India's position. Like most other countries, India follows a One-China policy. However, as external affairs ministry said, India emphasised that like the rest of the world it has a relationship with Taiwan focused on economic, technology and cultural ties, and this would continue. EAM raises with Wang trade curbs, dam on Brahmaputra The Indian side noted that China also cooperates with Taiwan in these very domains," the ministry said. India was among the first non-socialist countries to recognise People's Republic of China in 1950. While it never abandoned its One China policy, India stopped publicly articulating the same 15 years ago amid growing differences with Beijing on issues related to J&K and Arunachal Pradesh. Like most other countries, India doesn't have formal diplomatic or political ties with Taiwan. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it better to shower in the morning or at night? Here's what a microbiologist says CNA Read More Undo Jaishankar also underlined India's concerns with regard to the mega dam construction being undertaken by China in the lower reaches of the Yarlung Tsangpo (Brahmaputra), which will have implications for lower riparian states, said MEA. In the meeting on Monday, Jaishankar for the second time this year raised issues related to trade restrictions imposed by China. He had flagged it last month in a meeting with Wang on the margins of the SCO foreign ministers' meeting. China announced in April its decision to implement export controls on certain rare earth items. According to MEA, govt remained in touch with the Chinese side, in Beijing as well as in Delhi, to bring "predictability in supply chain for trade consistent with international practices". India's rare earth magnet import dependency on China has hovered at 80%-85% in the past three years. India has set up National Critical Mineral Mission to increase domestic capacity and build supply chain resilience in critical minerals. India had earlier also taken up with China the issue of restricted fertiliser supplies. Indian companies had in fact signed long-term agreements with their Saudi counterparts last month for continued supplies of DAP, the fertiliser most used in India after urea. China is one of the countries India has been dependent on for DAP supplies. A foreign ministry spokesperson in Beijing did not confirm if China was going to review export licences or if it was making an exemption for India but said China stood ready to strengthen dialogue and cooperation with relevant countries and jointly keep global industrial and supply chains stable. In his meeting with Jaishankar, Wang had said "in today's world, the changing situation is evolving rapidly, unilateral bullying practices are rampant, and free trade and the international order face severe challenges". Jaishankar too had underlined the imperative of working towards ensuring a stable global economy.
Economic Times
an hour ago
- Economic Times
Stock Radar: Bajaj Auto showing signs of reversal after falling over 30% from highs; medium term should ‘buy the dip'
Bajaj Auto Ltd, part of the automobile space, bounced back after taking support below the 100-DMA on the daily charts and is gradually moving traders with a high risk profile can look to buy the stock for a possible target of Rs 9,700 in the next 2-4 months, suggest 2-3-wheeler stock hit a high of Rs 12,772 on September 27, 2024, but it failed to hold the momentum. It closed at Rs 8,588 on August 18, 2025 which
Economic Times
an hour ago
- Economic Times
Aurobindo Pharma closing in on $5.5b Zentiva buyout
Boost to Aurobindo's European footprint Live Events Change of hands (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Mumbai: Aurobindo Pharma has emerged as the frontrunner to acquire Prague-based generic drugmaker Zentiva for $5-5.5 billion (Rs 43,500-47,900 crore) from Advent International , said several people aware of the matter, underscoring the growing consolidation of pharmaceutical assets in successful, this will be the largest-ever acquisition by an Indian pharma company, both at home and abroad, trumping the $3.2-billion acquisition of Daiichi Sankyo's stake in Ranbaxy in 2014, or Biocon Biologics' $3.3 billion cash and stock buyout of the global biosimilars business of US-based is competing with US private equity firm GTCR , the other serious contender left in the fray. Both sides are engaged in intense negotiations to finalise the various commercial and operations aspects of the late last year, Advent has been engaged with advisers Goldman Sachs and boutique investment bank PJT Partners to explore exit options for Zentiva, which it acquired seven years were made to several financial investors, including TPG and pharma competitors worldwide for a potential takeover.'The competition heated up from May. The binding offers have been submitted a few weeks ago and ongoing discussions have reached an advanced stage,' said a PE executive involved in the matter. 'Price is no longer being negotiated… A formal announcement can happen in the next fortnight or a month.'Zentiva will significantly boost Aurobindo's European footprint, specifically in the east European region–Czech Republic, Romania and Slovakia—where the market is seen as fertile and steadily warming up to a raft of biosimilars, following patent expiries of big prescription brands. Besides, as most healthcare spending in eastern Europe is led by government bulk public procurement, the returns are steadier as compared to perpetual price erosion in the revenues from Europe are already the highest among all other homegrown pharma peers. For calendar 2024, Zentiva Group's revenues were 1.7 billion euros ($1.98 billion) at an ebitda of 400 million euros ($467 million). Even then, analysts are surprised at the boldness of the bet that the Hyderabad-based company is willing to take amid heightened geopolitical risks and tariff market value stands at Rs 63,684.90 crore ($7.4 billion), whereas Zentiva is privately held. According to people aware of developments, Aurobindo has already secured a $4.75-billion credit line from MUFG–the sole financier in the transaction–as a bridge loan for the transaction. The remaining $800 million will be from the company's internal and Zentiva didn't respond to queries. Advent and MUFG declined to was the first to report on the Zentiva sale last November and on Aurobindo's interest in July this origins that can be traced back to Black Eagle Pharmacy from the 15th century, Zentiva was nationalised in 1946 and has undergone several ownership changes, including one in 1998 when the management team had taken over a majority share to refocus on branded generics. A decade later, in 2009, it got acquired by Sanofi and in 2018, got carved out by Advent for $2.4 billion, a deal process that had even seen a preliminary interest from India's Torrent the years, it has diversified its presence across categories such as prescription drugs, OTC products and consumer health and food supplements as well as geographies, growing both organically and through a series of buyouts across the region. It currently operates in 30 countries and has set a goal to reach one in five people across Europe by India, Zentiva has a manufacturing site in Gujarat. In 2022, Polish firm Pol Pharma, backed by a few private equity players, was reported to have placed a $3.5-billion bid for Zentiva, but the discussions remained inconclusive as the owners were reportedly considering a public leading drugmakers such as Biocon and, more recently, Lupin, have struck separate deals with Zentiva to push their biosimilars in the European region. Aurobindo is developing a robust pipeline of biosimilars such as denosumab (Prolia) for osteoporosis as well as omalizumab (Xolair) and bevacizumab (Avastin) for multiple cancer treatments.'While pricing pressure persists in chronic therapies, the European Union (EU) remains attractive for oncology and retail segments. Ongoing investments in EU-focused capacity continue to support volume growth,' said Amey Chalke of JM EU business of Aurobindo reported 9% revenue growth in the June quarter, from a year ago, with a strong performance across major markets and is on track to cross 1 billion euros in annual revenue in FY26. Injectables grew about 20% from the year earlier, driven by shortage-led demand. Two new oncology lines are being added to meet rising needs, as per the company also received four biosimilar approvals with commercial supplies initiated in the UK and full ramp-up expected in the third or fourth quarter of this fiscal. Aurobindo is targeting 40–60% margins in the EU biosimilar segment and aims for a blended 50% gross margin. Inhouse manufacturing now exceeds half the total formulations volumes, thereby boosting margins, inching toward 20% Aurobindo's FY25 consolidated sales of Rs 31,724 crore ($3.6 billion), the US market accounted for Rs 14,186 crore, up 6.8% from the year earlier. The European business grew 16.6% to Rs 8,356 month, Aurobindo acquired US-based contract development and manufacturing organization (CDMO) player Lannett for $250 million to shore up its manufacturing presence in the US while enhancing its capabilities in manufacturing complex generic drugs such as controlled at least three previous occasions, Aurobindo has either lost out to rivals or had to back out of marque transactions after announcing them. In 2020, it had to call off its deal to acquire the oral solids and dermatology business of Sandoz (part of Novartis) in the US for $900 million, failing to receive due approvals from US Federal Trade Commission even after two years.
